Medicus 2014;23(1):63-68
68
10. Chen K, Kolls JK. T cell-mediated host immune defenses in the lung.
AnnuRevImmunol2013;31:605–33.
11. WongMH,JohnsonMD.DifferentialresponseofprimaryalveolartypeI
andtypeIIcellstoLPSstimulation.PLoSOne2013;8:e55545.
12. AmsdenGW.Anti-inflammatoryeffectsofmacrolides–anunderappre-
ciatedbenefitinthetreatmentofcommunity-acquiredrespiratorytract
infections andchronic inflammatorypulmonary conditions? JAntimi-
crobChemother2005;55:10–21.
13. TessmerA,WelteT,MartusPisur.Impactofintravenous{beta}lactam/
macrolide versus {beta}-lactammonotherapy onmortality inhospitali-
zedpatientswithcommunity-acquiredpneumonia. JAntimicrobChe-
mother2009;63:1025–33.
14. Culić O, Ereaković V, Cepelak I i sur. Azithromycinmodulates neutrop-
hil functionandcirculating inflammatorymediators inhealthyhuman
subjects.EurJPharmacol2002;450:277–89.
15. He ZY, Ou LM, Zhang JQ i sur. Effect of 6months of erythromycin tre-
atment on inflammatory cells in induced sputumand exacerbations in
chronicobstructivepulmonarydisease.Respiration2010;80:445–52.
16. Kraft M, Cassell GH, Pak J, Martin RJ. Mycoplasma pneumoniae and
Chlamydia pneumoniae in asthma: effect of clarithromycin. Chest
2002;121:1782–8.
17. RollinsDR, BeutherDA,MartinRJ. Update on infectionandantibiotics
inasthma.CurrAllergyAsthmaRep2010;10:67–73.
18. Sharma S, Jaffe A, Dixon G. Immunomodulatory effects of macrolide
antibiotics in respiratory disease: therapeutic implications for asthma
andcysticfibrosis.PaediatrDrugs2007;9:107–18.
19. Altenburg J, de Graaff CS, van der Werf TS, Boersma WG. Immuno-
modulatory effects of macrolide antibiotics – part 2: advantages and
disadvantages of long-term, low-dose macrolide therapy. Respiration
2011;81:75–87.
20. López-Boado YS, Rubin BK. Macrolides as immunomodulatory medi-
cations for the therapy of chronic lung diseases. Curr Opin Pharmacol
2008;8:286–91.
21. Bermejo-Martin JF, Kelvin DJ, Eiros JM i sur. Macrolides for the tre-
atmentofsevererespiratoryillnesscausedbynovelH1N1swineinfluen-
zaviralstrains.JInfectDevCtries2009;3:159–61.
22. MiyamotoD,HasegawaS,SriwilaijaroenNisur.Clarithromycininhibits
progeny virus production from human influenza virus-infected host
cells.BiolPharmBull2008;31:217–22.
23. Zhirnov O, Klwnk HD. Human influenza A viruses are proteolytica-
lly activated and do not induce apoptosis in CACO-2 cells. Virology
2003;313:198–212.
24. Nimmerjahn F, Dudziak D, Dirmeier U i sur. Active NF-kappaB si-
gnalling is a prerequisite for influenza virus infection. J Gen Virol
2004;85:2347–56.
Prof. dr. sc. Alemka Markotić, dr. med.
Odjel za znanstvena istraživanja
Klinika za infektivne bolesti „Dr. Fran Mihaljević“
Mirogojska 8
10000 Zagreb
e-mail:
23. 10. 2013.
2. 12. 2013.
ADRESA ZA DOPISIVANJE:
PRIMLJENO/RECEIVED:
PRIHVAĆENO/ACCEPTED:
Markotić A.
